Skip to main content
Smart Investors Daily
GK

NYSE · GKOS

Glaukos Corporation

Healthcare · Medical - Devices

$238.10

Up+$5.02 (+2.15%)

Updated Nov 20, 2026, 2:14 AM

SID Score

6.5/10

Composite research score

Smart Money

58/100

Neutral

Market cap
6.27B
P/E ratio
-71.17
Dividend yield
0.00%
52-week range
$87.32 – $255.19
Volume
746.19K
Avg. volume
1.14M

Price performance · GKOS

GKOS price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 19, 2026

GKOS closed at $238.10 after 21 trading sessions, up 34.76% for the selected period.

Last close
$238.10
Period change
+34.76%
Period low
$176.69
Period high
$247.16
Daily close
View OHLC price history
GKOS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 19, 2026$234.80$239.34$231.61$238.10746.19K
Nov 18, 2026$245.67$246.90$232.16$233.081.13M
Nov 17, 2026$242.60$247.12$239.65$243.25718.4K
Nov 16, 2026$245.43$250.61$242.01$244.88865.46K
Nov 13, 2026$246.20$249.07$242.34$245.72546.46K
Nov 12, 2026$248.03$249.973$242.66$246.03808.48K
Nov 11, 2026$237.54$248.27$237.54$247.16915.62K
Nov 10, 2026$237.94$241.3499$235.09$236.19847.92K
Nov 9, 2026$228.75$239.18$226.17$238.74854.1K
Nov 6, 2026$221.51$229.05$219.0597$224.411.2M
Nov 5, 2026$250.00$250.40$218.765$219.982.04M
Nov 4, 2026$237.18$255.185$235.27$246.702.08M
Nov 3, 2026$240.94$240.94$230.00$233.0410.74M
Nov 2, 2026$235.00$243.74$232.29$238.611.67M
Oct 30, 2026$242.42$248.75$236.68$237.602.07M
Oct 29, 2026$211.00$243.7124$207.41$242.485.42M
Oct 28, 2026$181.94$187.94$174.75$181.431.88M
Oct 27, 2026$178.49$185.86$176.68$181.171.69M
Oct 26, 2026$177.35$181.65$176.43$178.271.07M
Oct 23, 2026$175.95$179.70$173.075$178.88961.19K
Oct 22, 2026$176.72$178.22$174.21$176.69885.77K

Latest GKOS news

The latest Smart Investors Daily articles mentioning GKOS.

GKOS research

Overview

Company profile and research snapshot.

Company profile

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$121.38
Implied upside
—
Analysts
—
GKOS recent ratings
DateFirmRatingTarget
Nov 16, 2026BTIGBuy—
Oct 29, 2026Truist SecuritiesBuy—
Oct 29, 2026CitigroupBuy—
Oct 29, 2026Wells FargoOverweight—
Oct 29, 2026Piper SandlerOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 14, 2026

Glaukos (GKOS) Stock Fair Value Rises After Analysts Lift Targets On Strong Q3

Glaukos is back on investor radar after analysts lifted their price targets into a range of about US$225 to US$248 per share. Those higher targets are tied to what research desks describe as strong Q3 2026 execution, raised sales guidance, and traction for products like iDose and Epioxa. In the sections that follow, you will see how this evolving analyst narrative around Glaukos may shape the way you track the stock from here. Analyst Price Targets don't always capture the full story. Head...

Yahoo · Nov 12, 2026

What Supports Glaukos Corporation (GKOS) for a Powerful Profit Cycle?

Artisan Partners, an investment management company, released its third-quarter 2026 investor letter for the “Artisan U.S. Small-Cap Growth Strategy”. The letter can be downloaded here. Global equities reached new highs despite elevated oil prices and rising interest rates, driven by resilient U.S. economic data and a revised GDP growth forecast. However, the bond market faced […]

Yahoo · Nov 8, 2026

Did Raised Sales Guidance Just Shift Glaukos (GKOS) Investment Narrative?

Glaukos reported third quarter 2026 sales of US$211.03 million and returned to profitability, raised full year 2026 net sales guidance to US$775 million to US$785 million, and issued preliminary 2027 net sales guidance of US$1 billion, alongside a shift from the S&P 600 to the S&P 400 and its Health Care sector index. The combination of stronger earnings, higher sales targets and index reclassification moves Glaukos into a mid cap benchmark set that can attract a different mix of...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.